In order to meet the biological constraints, In this paper we consider a system of four equations which captures T-cell-HIV interactions. It describes the behavior of normal T cells, latently-infected ...

A rare cell in the lining of lungs is fundamental to the organ-wide response necessary to repair damage from toxins like ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

The past few months have been rather gloomy in the health research space in Kenya. It all started with withdrawal of the USAID funding, bringing to a halt some ongoing research programmes in the ...

An outside group of experts agreed that the CDC should recommend a new antibody drug that offers protection against RSV for ...

The vote offers a sigh of relief to doctors and public health experts worried about vaccine skepticism creeping into policymaking.

Garegnani L, Styrmisdóttir L, Roson Rodriguez P, Escobar Liquitay CM, Esteban I, Franco JVA. Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. Cochrane ...

Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory infections for which effective treatment options remain limited. Herein, we employed a computational structure-based ...

"Scientists warn of bat virus just one mutation from infecting humans." ScienceDaily. ScienceDaily, 12 June 2025. <www.sciencedaily.com / releases / 2025 / 06 / 250612081312.htm>.

MPV tends to hit hardest in young children, older adults and people with weakened immune systems. A virologist explains.

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants.

U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV ...